title: Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus.
abstract: Staphylococcus aureus small-colony variants (SCVs) emerge frequently during chronic infections and are often associated with worse disease outcomes. There are no standardized methods for SCV antibiotic susceptibility testing (AST) due to poor growth and reversion to normal-colony (NC) phenotypes on standard media. We sought to identify reproducible methods for AST of S. aureus SCVs and to determine whether SCV susceptibilities can be predicted on the basis of treatment history, SCV biochemical type (auxotrophy), or the susceptibilities of isogenic NC coisolates. We tested the growth and stability of SCV isolates on 11 agar media, selecting for AST 2 media that yielded optimal SCV growth and the lowest rates of reversion to NC phenotypes. We then performed disk diffusion AST on 86 S. aureus SCVs and 28 isogenic NCs and Etest for a subset of 26 SCVs and 24 isogenic NCs. Growth and reversion were optimal on brain heart infusion agar and Mueller-Hinton agar supplemented with compounds for which most clinical SCVs are auxotrophic: hemin, menadione, and thymidine. SCVs were typically nonsusceptible to either trimethoprim-sulfamethoxazole or aminoglycosides, in accordance with the auxotrophy type. In contrast, SCVs were variably nonsusceptible to fluoroquinolones, macrolides, lincosamides, fusidic acid, and rifampin; mecA-positive SCVs were invariably resistant to cefoxitin. All isolates (both SCVs and NCs) were susceptible to quinupristin-dalfopristin, vancomycin, minocycline, linezolid, chloramphenicol, and tigecycline. Analysis of SCV auxotrophy type, isogenic NC antibiograms, and antibiotic treatment history had limited utility in predicting SCV susceptibilities. With clinical correlation, this AST method and these results may prove useful in directing treatment for SCV infections.
authors.affiliation: University of Washington, Seattle, Washington, USA.
authors.forename: Mimi R
authors.initials: MR
authors.lastname: Precit
authors.affiliation: University of Washington, Seattle, Washington, USA Seattle Children's Hospital, Seattle, Washington, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Wolter
authors.affiliation: Seattle Children's Hospital, Seattle, Washington, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Griffith
authors.affiliation: University of Washington, Seattle, Washington, USA Seattle Children's Hospital, Seattle, Washington, USA.
authors.forename: Julia
authors.initials: J
authors.lastname: Emerson
authors.affiliation: University of Washington, Seattle, Washington, USA Seattle Children's Hospital, Seattle, Washington, USA.
authors.forename: Jane L
authors.initials: JL
authors.lastname: Burns
authors.affiliation: University of Washington, Seattle, Washington, USA Seattle Children's Hospital, Seattle, Washington, USA lhoffm@uw.edu.
authors.forename: Lucas R
authors.initials: LR
authors.lastname: Hoffman
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics; D002440:Cefoxitin / Q000494:pharmacology; D024841:Fluoroquinolones / Q000494:pharmacology; D005672:Fusidic Acid / Q000494:pharmacology; D006801:Humans; D055231:Lincosamides / Q000494:pharmacology; D018942:Macrolides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D046915:Penicillin-Binding Proteins / Q000235:genetics; D012293:Rifampin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development* / Q000302:isolation & purification; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D024841:Fluoroquinolones; D055231:Lincosamides; D018942:Macrolides; D046915:Penicillin-Binding Proteins; C487789:mecA protein, Staphylococcus aureus; D005672:Fusidic Acid; D002440:Cefoxitin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D012293:Rifampin